Drug
Deupirfenidone (LYT-100)
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
Deupirfenidone (LYT-100) is a selectively deuterated form of pirfenidone that is designed to retain the potent and clinically-validated anti-fibrotic and anti-inflammatory activity of pirfenidone with a highly differentiated PK profile that has translated into favorable tolerability, as demonstrated by data from multiple human clinical studies.
Study Purpose
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
This drug has no clinical trials actively recruiting patients at this time.